| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1375467 | Bioorganic & Medicinal Chemistry Letters | 2005 | 5 Pages |
Abstract
5-Hydroxy-2-(2,6-diisopropylphenyl)-1H-isoindole-1,3-dione (5HPP-33: 10), which was obtained during our previous structural development studies on thalidomide, was revealed to possess potent anti-angiogenic activity in a human umbilical vein endothelial cell (HUVEC) assay. Thalidomide (1) and its metabolite, 5-hydroxythalidomide (5-HT: 2), which possesses a hydroxyl group at the position corresponding to that of 5HPP-33, as well as IMiDs (immunomodulatory derivatives of thalidomide: 3 and 5), also showed weak or moderate activity in the same assay.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Tomomi Noguchi, Haruka Fujimoto, Hiroko Sano, Atsushi Miyajima, Hiroyuki Miyachi, Yuichi Hashimoto,